SCHEMBL3331249

SCHEMBL3331249

CC1OC2=C(C(=O)C(=O)c3c2ccc2ccccc32)C1(C)C

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NQO1 P15559 3/20 0.50
POR P16435 3/20 0.50
DNMT1 P26358 1/20 0.48
ALDH1A1 P00352 7/20 0.40
MAPT P10636 6/20 0.40
MEN1 O00255 4/20 0.40
KMT2A Q03164 4/20 0.40
SMN1; SMN2 Q16637 3/20 0.40
RAB9A P51151 2/20 0.40
KDM4E B2RXH2 7/20 0.36
LMNA P02545 3/20 0.36
MAPK1 P28482 3/20 0.36
HPGD P15428 3/20 0.36
CES1 P23141 3/20 0.36
TDP1 Q9NUW8 2/20 0.36
CES2 O00748 1/20 0.36
KDM1A O60341 1/20 0.36
ACHE P22303 1/20 0.36
PTPN6 P29350 1/20 0.36
PTPN11 Q06124 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3329489 0.82 NQO1 (0.50) NQO1PORALDH1A1MAPTMEN1
(3R)-Dunnione SCHEMBL103115 0.77 NQO1 (0.63) NQO1PORALDH1A1MAPTMEN1
(3R)-Dunnione SCHEMBL29468606 0.77 NQO1 (0.63) NQO1PORALDH1A1MAPTMEN1
SCHEMBL6052838 0.76 NQO1 (0.57) NQO1PORALDH1A1MAPTMEN1
SCHEMBL8039547 0.74 DNMT1 (0.48) DNMT1ALDH1A1MAPTMEN1KMT2A
SCHEMBL3327381 0.73 DNMT1 (0.50) DNMT1ALDH1A1MAPTMEN1KMT2A
SCHEMBL19230419 0.72 DNMT1 (0.83) DNMT1ALDH1A1MAPTMEN1KMT2A
Alpha-Dunnione SCHEMBL940069 0.72 NQO1 (0.56) NQO1PORALDH1A1MAPTMEN1
SCHEMBL5940500 0.72 NQO1 (0.48) NQO1PORALDH1A1MAPTMEN1
(3R)-Dunnione SCHEMBL6052903 0.71 NQO1 (0.56) NQO1PORALDH1A1MAPTMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 29 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8404869-B2 Phenanthrenequinone-based compound and pharmaceutical composition containing the same for the treatment or prevention of disease involving metabolic syndrome MAZENCE INC. (KR) 2013-03-26 US claimed
US-20100137422-A1 NOVEL PHENANTHRENEQUINONE-BASED COMPOUND AND PHARMACEUTICAL COMPOSITION CONTAINING THE SAME FOR THE TREATMENT OR PREVENTION OF DISEASE INVOLVING METABOLIC SYNDROME YUNGJIN PHARM. CO., LTD. (KR) 2010-06-03 US claimed
EP-2137175-A1 NOVEL PHENANTHRENEQUINONE-BASED COMPOUND AND PHARMACEUTICAL COMPOSITION CONTAINING THE SAME FOR THE TREATMENT OR PREVENTION OF DISEASE INVOLVING METABOLIC SYNDROME Mazence Inc. (KR) 2009-12-30 EP claimed
WO-2008133441-A1 NOVEL PHENANTHRENEQUINONE-BASED COMPOUND AND PHARMACEUTICAL COMPOSITION CONTAINING THE SAME FOR THE TREATMENT OR PREVENTION OF DISEASE INVOLVING METABOLIC SYNDROME MAZENCE INC. (KR) 2008-11-06 WO claimed
US-20230255904-A1 PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING CANCER COMPRISING NAPHTHOQUINONE-BASED COMPOUND AND IMMUNE CHECKPOINT INHIBITOR AS ACTIVE INGREDIENTS NADIANBIO LTD. (KR) 2023-08-17 US disclosed
US-20230255904-A1 PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING CANCER COMPRISING NAPHTHOQUINONE-BASED COMPOUND AND IMMUNE CHECKPOINT INHIBITOR AS ACTIVE INGREDIENTS NADIANBIO LTD. (KR) 2023-08-17 US disclosed
EP-4180034-A1 PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING CANCER COMPRISING NAPHTHOQUINONE-BASED COMPOUND AND IMMUNE CHECKPOINT INHIBITOR AS ACTIVE INGREDIENTS NADIANBIO Ltd. (KR) 2023-05-17 EP disclosed
US-20140154319-A1 PHARMACEUTICAL COMPOSITION FOR THE TREATMENT AND PREVENTION OF CARDIAC DISEASE KWAK TAEHWAN (KR) 2014-06-05 US disclosed
US-20140154319-A1 PHARMACEUTICAL COMPOSITION FOR THE TREATMENT AND PREVENTION OF CARDIAC DISEASE KWAK TAEHWAN (KR) 2014-06-05 US disclosed
US-20130302422-A1 PHARMACEUTICAL COMPOSITION FOR TREATMENT AND PREVENTION OF KIDNEY DISEASES KT & G CORPORATION (KR) 2013-11-14 US disclosed
US-20130302422-A1 PHARMACEUTICAL COMPOSITION FOR TREATMENT AND PREVENTION OF KIDNEY DISEASES KT & G CORPORATION (KR) 2013-11-14 US disclosed
US-20120289577-A1 COMPOSITION FOR TREATING OR PREVENTING HEARING LOSS COMPRISING NAPHTHOQUINONE-BASED COMPOUNDS KT&G LIFE SCIENCES CORPORATION (KR) 2012-11-15 US disclosed
US-20100239685-A1 COMPOUND FOR TREATMENT OR PREVENTION OF PROSTATE-RELATED DISEASES AND PHARMACEUTICAL COMPOSITION OF COLON DELIVERY SYSTEM CONTAINING THE SAME KT & G CO., LTD. (KR) 2010-09-23 US disclosed
US-20100239674-A1 PHARMACEUTICAL COMPOSITION FOR THE TREATMENT AND PREVENTION OF DISEASES INVOLVING IMPOTENCE KT & G CO., LTD. (KR) 2010-09-23 US disclosed
US-20100239674-A1 PHARMACEUTICAL COMPOSITION FOR THE TREATMENT AND PREVENTION OF DISEASES INVOLVING IMPOTENCE KT & G CO., LTD. (KR) 2010-09-23 US disclosed
US-20100239685-A1 COMPOUND FOR TREATMENT OR PREVENTION OF PROSTATE-RELATED DISEASES AND PHARMACEUTICAL COMPOSITION OF COLON DELIVERY SYSTEM CONTAINING THE SAME KT & G CO., LTD. (KR) 2010-09-23 US disclosed
US-20100234453-A1 PHARMACEUTICAL COMPOSITION CONTAINING PHENANTHRENEQUINONE-BASED COMPOUND FOR INTESTINE DELIVERY SYSTEM KT & G CO., LTD. (KR) 2010-09-16 US disclosed
US-20100234453-A1 PHARMACEUTICAL COMPOSITION CONTAINING PHENANTHRENEQUINONE-BASED COMPOUND FOR INTESTINE DELIVERY SYSTEM KT & G CO., LTD. (KR) 2010-09-16 US disclosed
US-20100209513-A1 PHARMACEUTICAL COMPOSITION CONTAINING MICRONIZED PARTICLES OF NAPHTHOQUINONE-BASED COMPOUND KT&G CO., LTD. (KR) 2010-08-19 US disclosed
US-20100209513-A1 PHARMACEUTICAL COMPOSITION CONTAINING MICRONIZED PARTICLES OF NAPHTHOQUINONE-BASED COMPOUND KT&G CO., LTD. (KR) 2010-08-19 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130302422-A1 PHARMACEUTICAL COMPOSITION FOR TREATMENT AND PREVENTION OF KIDNEY DISEASES REN, ATP6V1B1, SLC5A1 NQO1 892/4885POR 1162/4885DNMT1 4879/4885
US-20120289577-A1 COMPOSITION FOR TREATING OR PREVENTING HEARING LOSS COMPRISING NAPHTHOQUINONE-BASED COMPOUNDS NQO1, MT-ND6, MT-ND5 NQO1 1/4885POR 2730/4885DNMT1 1488/4885
US-20230255904-A1 PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING CANCER COMPRISING NAPHTHOQUINONE-BASED COMPOUND AND IMMUNE CHECKPOINT INHIBITOR AS ACTIVE INGREDIENTS PDCD1, CD274, PDCD10 NQO1 17/4885POR 3903/4885DNMT1 3433/4885
US-20100234453-A1 PHARMACEUTICAL COMPOSITION CONTAINING PHENANTHRENEQUINONE-BASED COMPOUND FOR INTESTINE DELIVERY SYSTEM SLC10A2, SI, ABCB11 NQO1 224/4885POR 225/4885DNMT1 3790/4885
US-20140154319-A1 PHARMACEUTICAL COMPOSITION FOR THE TREATMENT AND PREVENTION OF CARDIAC DISEASE TNNT2, TNNC1, TNNI3 NQO1 773/4885POR 1472/4885DNMT1 4877/4885
US-20100209513-A1 PHARMACEUTICAL COMPOSITION CONTAINING MICRONIZED PARTICLES OF NAPHTHOQUINONE-BASED COMPOUND NDUFB10, NDUFB7, SQLE NQO1 38/4885POR 583/4885DNMT1 2675/4885
US-20100137422-A1 NOVEL PHENANTHRENEQUINONE-BASED COMPOUND AND PHARMACEUTICAL COMPOSITION CONTAINING THE SAME FOR THE TREATMENT OR PREVENTION OF DISEASE INVOLVING METABOLIC SYNDROME CYP27A1, CYP46A1, PCSK9 NQO1 121/4885POR 657/4885DNMT1 4516/4885
US-20100239685-A1 COMPOUND FOR TREATMENT OR PREVENTION OF PROSTATE-RELATED DISEASES AND PHARMACEUTICAL COMPOSITION OF COLON DELIVERY SYSTEM CONTAINING THE SAME KLK3, NR5A1, MAN2B2 NQO1 70/4885POR 1662/4885DNMT1 3731/4885
US-20100239674-A1 PHARMACEUTICAL COMPOSITION FOR THE TREATMENT AND PREVENTION OF DISEASES INVOLVING IMPOTENCE PDE3A, PDE3B, PDE2A NQO1 406/4885POR 667/4885DNMT1 4359/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.